Cowen and Company reaffirmed their buy rating on shares of Humana Inc. (NYSE:HUM) in a research report sent to investors on Friday. Cowen and Company currently has a $230.00 price target on the insurance provider’s stock.

Several other research firms have also commented on HUM. Credit Suisse Group reiterated an outperform rating and set a $250.00 price objective (up previously from $245.00) on shares of Humana in a research report on Thursday. Bank of America Corporation increased their price objective on shares of Humana from $270.00 to $275.00 and gave the company a buy rating in a research report on Friday. Citigroup Inc. assumed coverage on shares of Humana in a research report on Wednesday, June 28th. They set a buy rating and a $275.00 price objective for the company. UBS AG reiterated a neutral rating and set a $237.00 price objective (up previously from $205.00) on shares of Humana in a research report on Wednesday, June 28th. Finally, Cantor Fitzgerald reiterated a neutral rating on shares of Humana in a research report on Friday, June 23rd. Nine analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. The company has a consensus rating of Buy and an average target price of $231.00.

Shares of Humana (NYSE:HUM) traded down 0.64% during trading on Friday, reaching $237.56. 808,232 shares of the company were exchanged. The stock’s 50 day moving average is $232.54 and its 200 day moving average is $215.15. The company has a market capitalization of $34.28 billion, a price-to-earnings ratio of 24.21 and a beta of 0.91. Humana has a 1-year low of $150.00 and a 1-year high of $243.74.

Humana (NYSE:HUM) last released its quarterly earnings data on Wednesday, May 3rd. The insurance provider reported $2.75 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.55 by $0.20. Humana had a net margin of 2.71% and a return on equity of 14.38%. The business had revenue of $13.76 billion during the quarter, compared to analyst estimates of $13.61 billion. During the same quarter last year, the business earned $1.86 earnings per share. Equities analysts anticipate that Humana will post $11.15 earnings per share for the current year.

WARNING: “Humana’s (NYSE:HUM) “Buy” Rating Reaffirmed at Cowen and Company” was reported by Daily Political and is owned by of Daily Political. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this news story can be viewed at https://www.dailypolitical.com/2017/07/17/humanas-nysehum-buy-rating-reaffirmed-at-cowen-and-company.html.

The firm also recently announced a quarterly dividend, which will be paid on Monday, July 31st. Shareholders of record on Friday, June 30th will be given a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a yield of 0.67%. The ex-dividend date of this dividend is Wednesday, June 28th. Humana’s dividend payout ratio (DPR) is 16.24%.

In other Humana news, VP Heidi S. Margulis sold 1,500 shares of the firm’s stock in a transaction dated Friday, May 26th. The shares were sold at an average price of $231.96, for a total transaction of $347,940.00. Following the transaction, the vice president now owns 8,150 shares of the company’s stock, valued at approximately $1,890,474. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Brian P. Leclaire sold 4,971 shares of the firm’s stock in a transaction dated Wednesday, June 28th. The shares were sold at an average price of $240.00, for a total transaction of $1,193,040.00. Following the transaction, the senior vice president now directly owns 14,258 shares in the company, valued at approximately $3,421,920. The disclosure for this sale can be found here. Insiders have sold a total of 143,241 shares of company stock worth $32,446,903 in the last three months. Insiders own 0.80% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Atria Investments LLC increased its position in Humana by 112.5% in the first quarter. Atria Investments LLC now owns 3,594 shares of the insurance provider’s stock worth $741,000 after buying an additional 1,903 shares during the period. Capstone Asset Management Co. increased its position in Humana by 2.0% in the first quarter. Capstone Asset Management Co. now owns 16,805 shares of the insurance provider’s stock worth $3,464,000 after buying an additional 334 shares during the period. National Pension Service increased its position in Humana by 2.2% in the first quarter. National Pension Service now owns 115,193 shares of the insurance provider’s stock worth $23,830,000 after buying an additional 2,499 shares during the period. Gulf International Bank UK Ltd increased its position in Humana by 1.4% in the first quarter. Gulf International Bank UK Ltd now owns 46,205 shares of the insurance provider’s stock worth $9,524,000 after buying an additional 620 shares during the period. Finally, Contravisory Investment Management Inc. acquired a new position in Humana during the first quarter worth approximately $4,605,000. 99.04% of the stock is currently owned by institutional investors and hedge funds.

Humana Company Profile

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

Analyst Recommendations for Humana (NYSE:HUM)

Receive News & Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related companies with MarketBeat.com's FREE daily email newsletter.